Table 1 Investigational pneumococcal vaccines assessed in clinical trials
Vaccine formulation | Antigens of interest | Clinical trial phase | Vaccination route | Study outcome | Collaborators | Reference or source |
|---|---|---|---|---|---|---|
Polysaccharide-protein conjugate | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F and 33F | II | injected | Adults: tolerated & immunogenic. Toddlers: tolerated & immunogenic. Infants: ongoing tolerability & immunogenicity. | Merck & Co. Inc. | NCT01215175 NCT01215188 |
Protein-based sub-unit | PspA | I | injected | Adults: tolerated & immunogenic. | Aventis Pasteur | [87] |
PcsB, StkP, PsaA | I | injected | Adults: tolerated & immunogenic. | Intercell AG, PATH | [108] NCT00873431 | |
PhtD, PcpA, PlyD1, PcpA/PhtD | I | injected | Adults: tolerated and induced functional PlyD1 antibody. Functional post-immune human anti-PhtD antibody. Bangladeshi adults, toddlers & infants: ongoing tolerability & immunogenicity. | Sanofi Pasteur, Covance Clinical Research Unit | NCT01444352 NCT01444001 NCT01444339 | |
Protein-conjugate | dPly, PhtD/dPly, dPly/PHiD-CV, PhtD/dPly/PHiD-CV | II | injected | Toddlers: tolerated and immunogenic. Gambian infants & toddlers: ongoing immunogenicity & carriage. | GSK Biologicals, PATH, The London School of Hygiene and Tropical Medicine, Medical Research Council Unit | NCT00707798 NCT00896064 NCT00985751 NCT01262872 |
Whole cell | Killed, non-encapsulated S. pneumoniae | I | injected | Adults: ongoing safety & immunogenicity. | PATH, Children’s Hospital Boston | NCT01537185 |
Live, avirulent PspA-expressing Salmonella enterica serovar Typhimurium | I | oral | Adults: ongoing safety & immunogenicity. | Arizona State University | NCT01033409 |